Overview
Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company uses gene therapy and immunotherapy to develop treatments for cancer, as well as neurodegenerative and ocular diseases. Its four ocular gene therapies are partnered with Sanofi; the company works with Pfizer on another targeted antibody therapy. The company has three lead products: TroVax, ProSavin, and RetinoStat (being developed with Sanofi). TroVax
...
Read More is in late-stage clinical trials for the treatment of prostate cancer. ProSavin is being tested to treat Parkinson's disease using the company's LentiVector platform. RetinoStat is in clinical trials to treat wet age-related macular degeneration.
Read Less
Read More is in late-stage clinical trials for the treatment of prostate cancer. ProSavin is being tested to treat Parkinson's disease using the company's LentiVector platform. RetinoStat is in clinical trials to treat wet age-related macular degeneration.
Read Less
Robert Evgeniev Ghenchev
See more contacts
Other Professional, Scientific, and Technical Services
,
Professional, Scientific, and Technical Services
,
Commercial nonphysical research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Scientific Research and Development Services
,
Specialized Design Services
?
?
Estimated
$163.27 million
Actual
43.84%
$231
DEC
?
?
London SETS:OXB
Contacts
Get in Touch with 12 Principals* and 157 Contacts
-
Robert Evgeniev GhenchevDirector
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$163.27 million
USD
Actual
1 USD = 0.7888 GBP
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$64 | -$36 | -$16 |
| Net Investing Cash | $7 | $4 | -$72 |
| Net Financing Cash | $4 | -$16 | $125 |
| Net Change in Cash | -$53 | -$49 | $37 |
| Cash at Beginning of Period | $131 | $179 | $138 |
| Cash at End of Period | $77 | $131 | $179 |
| Capital Expenditure | -$10 | -$12 | -$21 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $77 | $131 | $179 |
| Accounts Receivable | $30 | $10 | $43 |
| Inventories | $17 | $16 | $16 |
| Other Current Assets | $45 | $21 | $35 |
| Asset Summary | |||
| Total Current Assets | $169 | $179 | $273 |
| Tangible Fixed Assets | $82 | $96 | $170 |
| Intangible Assets | $37 | $39 | $133 |
| Total Assets | $232 | $252 | $460 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $12 | $8 | $17 |
| Short-Term Debt | $0 | $ | $ |
| Other Current Liabilities | $61 | $49 | $58 |
| Liability Summary | |||
| Total Current Liabilities | $74 | $56 | $76 |
| Long-Term Debt | $50 | $49 | $50 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $217 | $221 | $284 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $67 | $61 | $61 |
| Retained Earnings | -$506 | -$447 | -$252 |
| Equity Summary | |||
| Total Equity | $72 | $94 | $259 |
| Shares Outstanding | 105,959,899 | 96,803,053 | 96,263,165 |